New Products

Telesis Bio, a San Diego-based synthetic biology company, has launched BioXp Select Kits for the BioXp Automated Synthetic Biology Workstation. The BioXp Select DNA Cloning and Amplification Kit and the BioXp Select Plasmid Amplification Kit enable on-demand and automated synthesis and amplification of transfection-scale DNA using customers' own DNA fragments or plasmid DNA, overnight and at the push of a button. The company noted that running these kits on the BioXp System can accelerate discovery, particularly in the areas of antibody discovery, cellular immunotherapy, and protein engineering.

Tianlong of Xi'an, China, has globally launched the GeneFlex Nucleic Acid Extractor and Gentier Mini+ Real-Time PCR System.

The GeneFlex system can form 16 x n different throughputs, enabling simultaneous extraction in different projects without manual interference. It features a sample processing volume of 200 μL to 500 μL, with larger sample volumes enabling a higher yield of nucleic acid. It also features precise temperature control with a range of 30° C to 120° C, a heating speed of 4° ±0.2 °C/s, temperature accuracy of ±1° C, and temperature uniformity of ≤1.0° C. This enables researchers to achieve reproducible results with high accuracy, the company said.

The Gentier Mini+ Real-Time PCR System is lightweight at 3.2 kgs and features a 7-in. full-color LCD touchscreen monitor. It can perform fluorescence scanning of all 16 wells in 1 second, and has multiple interconnectivity methods, including network port, USB, and Wi-Fi, the company said.

Fujirebio has launched the Lumipulse G ApoE4 and G Pan-ApoE Assays for research use only on the fully automated Lumipulse G Systems. These chemiluminescent enzyme immunoassays enable the quantitative measurement of the E4 isoform of the apolipoprotein E (ApoE4), specifically, and for all isoforms of the same protein (Pan-ApoE), respectively, in human plasma within just 35 minutes. The company said that researchers can use the assays to further investigate the clinical utility of ApoE protein quantification in Alzheimer's disease and related disorders on the Lumipulse G. This platform has the required throughput and meets the regulatory requirements to support possible future routine use of blood-based testing of these markers, Fujirebio added.

BioEcho Life Sciences has launched the EchoLution FFPE DNA kit for nucleic acid extraction.

The kit enables extraction from any formalin-fixed, paraffin-embedded tissue sample for PCR, sequencing, and epigenetic analysis. The kit requires fewer steps and offers single-step purification, resulting in a protocol up to 70 percent faster than other kits on the market, according to the company.

Illumina has released Connected Insights, a cloud-based software for tertiary analysis of clinical next-generation sequencing data.

Connected Insights builds on the firm's Connected Software portfolio and is designed to streamline interpretation and reporting. The initial release supports somatic oncology applications. The software integrates third-party knowledge bases, including the Jackson Laboratory's Clinical Knowledgebase, to reduce turnaround time of clinical reporting.

Connected Insights is assay-agnostic and compatible with variant calling files (VCF) from any secondary analysis solution, including Illumina's Dragen secondary analysis. Connected Insights supports a wide range of DNA and RNA assays with VCF output, including targeted and comprehensive genomic profiling panels, whole-exome and whole-genome sequencing, and transcriptomic data from both tissue and liquid samples.

The product is undergoing beta testing in the US but is commercially available in a "limited number" of countries.

Dante Genomics has released the beta version of Avanti, software for large-scale variant interpretation and report writing. By running on parallel servers, the web-based Avanti takes whole-genome, whole-exome, targeted panel, and other next-generation sequencing VCF and FASTQ files and produces complete reports within five minutes, according to the company. Dante draws from a catalog of 125 reports to perform secondary and tertiary analysis with the new Avanti software.

Stilla Technologies has introduced the Ruby chip, a 'load-and-go' consumable for digital PCR that is optimized for the Naica system. The Ruby chip has adjustable throughput to process up to 96 samples in under three hours with standard SBS plate spacing that is compatible with multichannel pipettes for manual loading as well integration with common liquid handling robots. The chip comes ready to use and preloaded with sealed chambers, enabling the addition of sample mix in a single, foil-piercing pipetting step to eliminate cross contamination and reduce handling.

Bio-Rad has launched the PTC Tempo 96 and PTC Tempo Deepwell thermal cyclers. The instruments have refreshed, intuitive user interfaces and flexible connectivity features for streamlining protocol management, Bio-Rad said. They also have motorized lids for automation compatibility, Wi-Fi, ethernet, USB, cloud connectivity, and a secure user mode for regulated environments.

Synthetic DNA maker Elegen has launched its Enfinia DNA product. Enfinia DNA is available at lengths up to 7 Kb with per-base accuracy of approximately 99.999 percent, according to the company. Constructs are made in the US with turnaround time of seven business days.

Bionano Laboratories, the clinical services arm of Bionano Genomics, has launched two new optical genome mapping (OGM)-based laboratory-developed tests (LDTs), OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV. The postnatal assay tests peripheral blood samples from individuals who have been diagnosed with autism spectrum disorder (ASD), intellectual disability, developmental delay, epilepsy and rare undiagnosed genetic disease, and others. According to the company, the report of this test will include a whole genome analysis of structural variants (SVs) and will screen for the common CGG expansion in the FMR1 gene that may indicate fragile X syndrome.

The prenatal test may be indicated for fetuses where a genetic anomaly is suspected, including abnormal ultrasound or positive non-invasive prenatal screening (NIPS), previous child with chromosomal abnormality, and history of recurrent pregnancy loss, the company said. This test will generate a report that includes whole-genome analysis to assess for SVs of diagnostic and prognostic value.